CervoMed Inc. (CRVO) Financial Statements
Industry: Pharmaceutical Preparations
In fiscal 2025, CervoMed reported revenue of $4.0M, down 58.9% from $9.7M the year before. Net income was -$27.0M (a -673.1% net margin). Operating margin was -706.2%. Operating activities generated -$23.4M of cash. At fiscal year end, CervoMed held $22.9M in total assets against $4.7M in total liabilities, including $8.2M of cash and equivalents.
Open the full interactive CervoMed financials → Quarterly statements, key ratios, valuation history and price charts.
CervoMed Key Stats
| Share Price | $2.27 |
|---|---|
| Market Cap | $23.3M |
| Revenue YoY Growth | -58.9% |
| 52-Week Range | $2.25 – $9.94 |
| Shares Outstanding | 10.2 million (basic, 2026 Q2) |
CervoMed Income Statement
| FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $7.1M | $9.7M | $4.0M |
| Operating Income | -$16.0M | -$24.7M | -$16.0M | -$7.8M | -$18.2M | -$28.3M |
| Pre-Tax Income | -$15.9M | -$24.5M | -$15.6M | -$2.2M | -$16.3M | -$27.0M |
| Income Tax | -$1.7M | -$443,893 | $0 | — | — | $0 |
| Net Income | -$14.2M | -$24.1M | -$15.6M | -$2.2M | -$16.3M | -$27.0M |
| Diluted EPS | $4037397975.00 | $7322006100.00 | $3058336.50 | — | — | — |
CervoMed Quarterly Results
| 2025 Q3 | 2025 Q4 | 2026 Q1 | 2026 Q2 | |
|---|---|---|---|---|
| Revenue | $322,569 | $8,726 | $0 | $0 |
| Net Income | -$7.7M | -$8.1M | -$8.0M | -$6.6M |
CervoMed Balance Sheet
| FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|---|
| Cash & Equivalents | $18.5M | $37.3M | $10.1M | $7.8M | $9.0M | $8.2M |
| Current Assets | $18.8M | $37.8M | $22.6M | $10.0M | $43.1M | $22.9M |
| Total Assets | $27.7M | $37.8M | $22.6M | $10.0M | $43.1M | $22.9M |
| Current Liabilities | $2.4M | $2.9M | — | — | — | $4.7M |
| Total Liabilities | $2.9M | $2.9M | $2.4M | $2.6M | $3.9M | $4.7M |
| Shareholders' Equity | $24.8M | $34.9M | $20.2M | $7.4M | $39.2M | $18.2M |
CervoMed Cash Flow Statement
| FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|---|
| Cash From Operations | -$13.6M | -$14.5M | -$15.0M | -$7.4M | -$16.5M | -$23.4M |
| Cash From Investing | — | $4,000 | -$12.2M | — | -$28.7M | $18.1M |
| Cash From Financing | $17.9M | $33.3M | $5,000 | $11.1M | $46.4M | $4.6M |
Figures from CervoMed's 10-K and 10-Q filings with the SEC, as of 2026-10-14. Fiscal years follow the company's own reporting calendar. EPS and share counts are adjusted for later stock splits. See the full CervoMed financials page for every line item.
CervoMed Company Profile
| Ticker | CRVO |
|---|---|
| Exchange | Nasdaq |
| Industry | Pharmaceutical Preparations |
| Headquarters | Boston, Massachusetts |
| Incorporated in | Delaware |
| Fiscal Year End | December 31 |
| SEC Filer Category | Non-accelerated filer, smaller reporting company |
| SEC CIK | 0001053691 |
Frequently Asked Questions
What was CervoMed's revenue in fiscal 2025?
CervoMed (CRVO) reported revenue of $4.0M for fiscal 2025.
What is CervoMed's annual revenue history?
CervoMed's annual revenue by fiscal year: 2020: $0; 2021: $0; 2022: $0; 2023: $7.1M; 2024: $9.7M; 2025: $4.0M.
What was CervoMed's net income in fiscal 2025?
CervoMed reported net income of -$27.0M for fiscal 2025.
What was CervoMed's revenue last quarter?
In its most recent reported quarter (2026 Q2), CervoMed reported revenue of $0.
How many shares of CervoMed are outstanding?
CervoMed reported a weighted average of 10.2 million basic shares outstanding in 2026 Q2.
What is CervoMed's market cap?
Based on its latest closing price, CervoMed (CRVO) has a market capitalization of about $23.3M.
When does CervoMed's fiscal year end?
CervoMed's fiscal year end, as registered with the SEC, is December 31.
Where is CervoMed headquartered?
CervoMed lists its business address in Boston, Massachusetts in its SEC filings.